Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, offering investors a direct opportunity to engage with the company's leadership.
The company plans to highlight recent progress across its pipeline and platforms, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This milestone reflects Oncotelic's commitment to moving its lead candidate through clinical development efficiently. Additionally, the expansion of European clinical sites signals the company's dedication to broadening its trial reach and enhancing patient access across geographies.
A key focus of the presentation will be the validation of Oncotelic's Deciparticle™ platform through peer-reviewed publications. This proprietary drug delivery technology is designed to improve the therapeutic index of drugs, potentially leading to better efficacy and reduced toxicity. The validation in scientific literature adds credibility to the platform and strengthens the company's intellectual property position.
Oncotelic also continues to develop its scalable cGMP manufacturing capabilities, which are critical for transitioning from clinical to commercial production. The ability to manufacture at scale is a significant competitive advantage in the biotech industry, as it reduces reliance on third-party vendors and allows for more control over supply chain and quality.
Furthermore, the company is advancing its AI-driven drug discovery, robotics, and nanomedicine platforms. These cutting-edge technologies are intended to accelerate the identification of novel drug candidates and optimize their delivery, positioning Oncotelic at the forefront of precision medicine.
Dr. Vuong Trieu's presentation at the OTCQB Virtual Investor Conference is a strategic opportunity to communicate these advancements to the investment community. By sharing these updates, Oncotelic aims to demonstrate its progress and the potential value of its diverse pipeline. Investors interested in the latest news and updates regarding OTLC can visit the company's newsroom at https://nnw.fm/OTLC.
For more information about the conference and to access the live presentation, interested parties can refer to the full press release at https://nnw.fm/fGHUt. Oncotelic's participation in this event underscores its proactive approach to investor relations and transparency, which is essential for building trust and support among shareholders.
As Oncotelic continues to achieve clinical milestones and expand its technological capabilities, the company remains dedicated to its mission of developing innovative therapies that can improve patient outcomes. The upcoming presentation is expected to provide clarity on the company's strategic direction and near-term catalysts, which could be pivotal for its growth trajectory.
